Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-486 plus venetoclax in previously untreated higher-risk myelodysplastic syndromes
2024-514876-41-00Phase 2Authorised
- Sponsor
- Groupe Français des Myélodysplasies
- Start
- Oct 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of azacitidine and venetoclax in myelodysplastic syndrome (MDS), sponsored by Groupe Français des Myélodysplasies. Primary endpoints: Dose-limiting toxicity and Overall response. Planned start Oct 2024; status: authorised.
02
Drugs
azacitidinevenetoclax
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2024-514876-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514876-41-00.